Resonance Health is delighted to provide you with our latest customer newsletter, where you can find an update on all our latest acitvities. To read the newsletter please click here

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to advise that Mr. Nick Allan has accepted an offer of employment with the Resonance Health group as Chief Financial Officer & Company Secretary (“CFO & Co Sec”) commencing on 31 May 2021.

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to advise that Mr. Nick Allan has accepted an offer of employment with the Resonance Health group as Chief

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to announce that it has received CE mark for HepaFat-AI, the Company’s fully automated artificial intelligence (“AI”) software that assesses liver fat (the “Device”).

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to announce that it has received CE mark for HepaFat-AI, the Company’s fully automated artificial intelligence (“AI”) software that

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to announce that it has received Australian Therapeutic Goods Administration (“TGA”) approval for HepaFat-AI, the Company’s fully automated artificial